Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Novo Nordisk has such a blockbuster with Wegovy ... see our special series The Obesity Revolution.
RFK Jr.'s confirmation hearings continue today as he appears before a second Senate committee. Follow STAT's live updates.
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...